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Objective: We sought to determine the mechanism or
mechanisms of immune suppression mediated by the
nanovesicles.
Methods: T-cell tolerance was induced by means of intravenous
injection of hapten conjugated to self-antigens of syngeneic
erythrocytes and subsequent contact immunizationwith the same
hapten. Lymph node and spleen cells from tolerized or control
donors were harvested and cultured to produce a supernatant
containing suppressive nanovesicles that were isolated from the
tolerized mice for testing in active and adoptive cell-transfer
models of CS.
Results: Tolerance was shown due to exosome-like nanovesicles
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170nanovesicles was conferred by a surface coat of antibody light
chains or possibly whole antibody, allowing targeted delivery of
selected inhibitory microRNA (miRNA)–150 to CS effector T
cells. Nanovesicles also inhibited CS in actively sensitized mice
after systemic injection at the peak of the responses. The role of
antibody and miRNA-150 was established by tolerizing either
panimmunoglobulin-deficient JH2/2 or miRNA-1502/2 mice
that produced nonsuppressive nanovesicles. These nanovesicles
could be made suppressive by adding antigen-specific antibody
light chains or miRNA-150, respectively.
Conclusions: This is the first example of T-cell regulation
through systemic transit of exosome-like nanovesicles delivering
a chosen inhibitory miRNA to target effector T cells in an
antigen-specific manner by a surface coating of antibody light
chains. (J Allergy Clin Immunol 2013;132:170-81.)
Key words: Exosomes, exosome-like nanovesicles, nanovesicles,
T-cell suppression, miRNA, miRNA-150, antibody light chains, aller-
gic cutaneous contact dermatitis, contact sensitivity
Exosomes are nanovesicles generated intracellularly by bud-
ding from the multivesicular bodies of the terminal endosomal
pathway, where they accumulate and are released from the cell
during exocytosis of themultivesicular bodies.1,2 Exosomes or re-
lated vesicles are produced by all cell types in virtually all species
and have been found in all fluids studied. Their outstanding prop-
erty is that they contain a cargo of donor cell proteins, mRNAs,
and microRNAs (miRNAs) that are delivered extracellularly to
acceptor cells, where they can function.3-6 Thus the vesicular
transport of proteins can drive or inhibit signaling pathways.5-7
mRNA can translate donor cell proteins,3,4 and delivered miRNA
can bind acceptor cell mRNA to regulate protein translation.3,4,8,9
Contact sensitivity (CS) in mice is a major model of the clinical
allergic skin diseases contact dermatitis and atopic dermatitis.
Additionally, CS is a model of delayed-type hypersensitivity
mechanisms that participate in other T cell–mediated processes,
such as in T-cell aspects of autoimmunity, transplantation,
infection resistance, and cancer. Furthermore, the effector phase
of CS has been shown recently to have unanticipated complexity.
The new findings established that sensitization involves Toll-like
receptors10; initiation of elicitation involves B-1 B cells, invariant
natural killer (NK) T cells, IL-4, mast cells, platelets, endothelial
cells, and complement11; and responses can be mediated by CD4,
CD8,12 or TH17
13 T cells and even NK cells.14 Finally, there is
now recognition of regulation of CS by either regulatory T
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BRYNIARSKI ET AL 171Abbreviations usedAb LC: Free antibody light chainCS: Contact sensitivityDPBS: Dulbecco PBSFoxp3: Forkhead box protein 3FT: Flow throughhrIL-2: Human recombinant IL-2miRNA: MicroRNANK: Natural killerNl Cell Sup: Supernatant from culture of lymph and spleen cells from
normal (nonimmunized) miceNTA: Nanoparticle tracking analysisOX: OxazoloneTNP: TrinitrophenylTreg: Regulatory TTs: Suppressor T cells from antigen-tolerized miceTs Sup: Supernatant from culture of lymph and spleen suppres-
sor T cells from tolerized mice(Treg) cells15 or myeloid suppressor cells.16 The present study
presents evidence of yet another regulatory pathway involving
suppressor T cells producing antigen-specific exosome-like nano-
vesicles that deliver inhibitory miRNA.
Such exosomal transport of functional miRNAs passing
genetic information between donor and acceptor cells has been
confirmed in diverse instances3,4,8,9 and has provided insight into
new levels of regulation between cells in the immune sys-
tem.10-12 Exosome targeting usually is paracrine,5,6,17-23 but
there also is endocrine transport of exosome-like nanovesicles
through the bloodstream, enabling regulation of distant acceptor
cell function,24-26 as seen here. The current study presents new
evidence of a cell-to-cell suppressive pathway involving CD81
suppressor T cell–derived exosome-like nanovesicles that
antigen-specifically target the effector T-cell mixture of CS by
delivering inhibitory miRNAs. Selection of the particular antigen
specificity and the inhibitory miRNA shown here opens up sig-
nificant translational possibilities for the treatment of a variety
of human diseases.METHODS
Description of the materials and methods used in this study can be
found in the Methods section in this article’s Online Repository at www.
jacionline.org.RESULTS
High-dose antigen tolerance induces suppressor
T cells that produce inhibitory supernatant
We found that high trinitrophenyl (TNP) antigen dose toler-
ance induced suppressor T cells from antigen-tolerized mice
(Ts) and that supernatant from culture of lymph and spleen
suppressor T cells from tolerized mice (Ts Sup) contained all
their suppressive activity for CS effector cells (Fig 1, A, group C
vs groups B and D). We suspected that vesicles in the Ts Sup
might be responsible for the suppression. Therefore putative ves-
icles were enriched by means of progressive ultrafiltration and
differential centrifugation, culminating in pelleting by means
of two 100,000g ultracentrifugations.1,2 The final pellet con-
tained 130-nm nanovesicles resembling exosomes, as deter-
mined by means of electron microscopy (Fig 1, B, right) andnanoparticle tracking analysis (NTA; Fig 1, C).27 Like exo-
somes, these nanovesicles expressed tetraspanins, such as
CD9, by means of immunoblotting (Fig 1, D) and CD3 and
T-cell receptor b by means of flow cytometry (data not shown),
confirming their T-cell origin.
The final 100,000g pellet from oxazolone (OX)–Ts-Sup from
mice tolerized with OX-labeled mouse red blood cells compared
with the supernatant above the pellet contained the Ts Sup abil-
ity to suppress adoptive transfer of OX CS effector T cells
(Fig 2, A, group D vs group C). Identical results were obtained
in the TNP CS system (data not shown). Furthermore, a dose-
response experiment in the TNP CS system was done to test
the potency and validity of the suppressive nanovesicles and
showed a decreasing suppression of adoptive CS by the resus-
pended serially diluted Ts Sup pellet nanovesicles (see Fig
E1, groups D, E, and F, in this article’s Online Repository at
www.jacionline.org), whereas those from the supernatant from
culture of lymph and spleen cells from normal (nonimmunized)
mice (Nl Cell Sup) pellet at the high dose were not suppressive
(group C). Finally, resuspension of the 100,000g pellet and re-
peated ultracentrifugation on a sucrose gradient resulted in
buoyant fractions. Only the fraction that showed buoyancy iden-
tical to that of exosomes1,2 suppressed adoptive transfer of CS
(Fig 2, B, group E), like the starting TNP–Ts Sup nanovesicles
(Fig 2, B, group D). Considering all the above characteristics,
we henceforth called these suppressive CD81 T cell–derived
vesicles exosome-like nanovesicles.An in vitro non–antigen-specific assay confirms the
in vivo suppressive function of the Ts Sup–derived
nanovesicles
To further confirm the above, a non–antigen-specific in vitro as-
say was used to test inhibition of the HT-2 T-cell line responsive-
ness to IL-2 by the exosome-like nanovesicles. The end point was
the lowest number of serially diluted nanovesicles that resulted in
at least 50%HT-2 cell viability. This assay confirmed the suppres-
sive activity of the Ts Sup exosome-like nanovesicles (Fig 3, C,
group B).Another in vitro but antigen-specific assay
confirmed suppressive activity of Ts Sup
exosome-like nanovesicles
Here immunobead-isolated CD41 CS effector T cells re-
sponded in vitro to TNP-linked dendritic cells by producing
IFN-g. Shown are 4 separate experiments confirming that the
100,000g pellet–derived exosome-like nanovesicles from Ts
Sup suppressed IFN-g production, whereas similar Nl Cell Sup
nanovesicles did not (see Fig E2 in this article’s Online Reposi-
tory at www.jacionline.org).Suppressive exosome-like nanovesicles are derived
from CD81 T cells, are present in the plasma of Ts
donors, and are not derived from Treg cells
Depletion of CD81 cells from the Ts Sup cell culture with anti-
CD8mAb plus complement (Fig 3,A, group C) or with anti-CD8–
conjugated versus anti-CD4–conjugated beads (data not shown)
removed the ability to generate suppressive supernatant.
Furthermore, blood plasma from the high-dose antigen–tolerized
FIG 1. High-dose antigen tolerization of the CS immune response induces Ts cells producing Ts Sup
containing exosome-like nanovesicles. A, Ts cells (group B) or their culture supernatant (Ts Sup, group C)
suppressed adoptive transfer of CS. B, Electron microscopy revealed that Nl Sup, sham supernatant, and
TNP–Ts Sup pellets contained nanovesicles resembling exosomes at 80,000 times magnification. Bar 5
65 nm. C, NTA showed homogenously sized nanovesicles from control RAW cell line supernatant and
from TNP–Ts Sup pellets, indicating particle size/concentration. D, Western immunoblotting showed CD9
tetraspanin expression by extracts of pellets from TNP–Ts Sup, Nl Cell Sup, sham supernatant (Sham cell
Sup), and RAW cell line Sup compared with control RAW cell lysate.
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pellet also contained suppressive nanovesicles (Fig 3, B, group
E), whereas similar Nl Cell and sham plasma-derived nanove-
sicles had none (Fig 3, B, groups F and G). In support of these
findings, the in vitro, IL-2–dependent, HT-2 cell, non–antigen-
specific assay showed strong suppressive activity of plasma
exosome-like nanovesicles from tolerized mice versus normal
mice (Fig 3, C, group D vs group C). Finally, we tested
whether Treg cells were involved using DEREG mice.28
High-dose antigen tolerance resulted in exosome-like nanove-
sicles that had equivalent suppressive ability when derived
from the Treg cell–depleted mice compared with wild-type
mice (Fig 3, D).Suppressor T-cell exosome-like nanovesicles inhibit
active cutaneous CS responses in vivo
We tested whether the nanovesicles could act in vivo when di-
rectly injected into actively sensitized mice that were already
expressing a CS response. Nanovesicles were administered in-
traperitoneally at the 24-hour peak response (Fig 4, open cir-
cles). Then the subsequent time course of ear swelling was
compared with that of actively sensitized untreated and ear-
challenged mice (Fig 4, squares) and with that of recipients of
control vesicles from sham-tolerized mice (Fig 4, triangles).
Ts Sup exosome-like nanovesicles strongly suppressedsubsequent ear swelling at 48 and 72 hours by 53% and 60%,
respectively (Fig 4), whereas sham supernatant nanovesicles
did not. Furthermore, similar in vivo treatment with the nanove-
sicles showed that suppression could last up to 120 hours after a
single injection (see Fig E3, A, triangles, in this article’s Online
Repository at www.jacionline.org), and significant inhibition
even occurred when nanovesicles were administered orally
(see Fig E3, B, group D).Suppression by exosome-like nanovesicles is
antigen specific through a dual reciprocal antigen
specificity test
Preliminary results suggested functional antigen specificity of
the suppressive nanovesicles. This was confirmed by using a dual
reciprocal antigen criss-cross experiment that demonstrated that
nanovesicles from TNP-tolerized mice only suppressed TNP CS
effector cells (Fig 5, A, group B) and not CS responses to OX, an-
other hapten antigen (Fig 5, A, group E). Similarly, exosome-like
nanovesicles from OX hapten–tolerized mice suppressed OX CS
effector cells (Fig 5, A, group F) but not TNP CS effector T cells
(Fig 5, A, group C). To possibly account for antigen specificity,
flow cytometry showed antibody kappa light chains (Ab kappa
LC) on the surfaces of nanovesicles from tolerized mice (Fig 5,
B, right, red peak vs gray isotype control) compared with the con-
trol macrophage cell line (Fig 5, B, left, blue peak vs gray isotype
FIG 2. Ts Sup function is entirely in the 100,000g pellet and in the buoyant fraction of a discontinuous su-
crose gradient. A, The OX–Ts Sup pellet was suppressive (group D), whereas OX–Ts Sup depleted of nano-
vesicles (group C), starting Nl Sup (group E), Nl Sup pellet (group F), and Nl Sup depleted of nanovesicles
(group G) were nonsuppressive. B, Vesicles from the TNP–Ts Sup 1.86/1.08 buoyant fraction (group E) and
vesicles from the original Ts Sup pellet (group D)were suppressive, whereas the pellet depleted of buoyant
material (group F) and Nl Cell Sup fractions (groups B and C) were not inhibitory.
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antibody light chain (Ab LC) on the nanovesicle surface could
provide a mechanism for antigen specificity.Tolerization of panimmunoglobulin-deficient JH2/2
mice confirms that antigen specificity was due to
antibody on the surface of the exosome-like
nanovesicles
We found that nanovesicles from tolerized panimmunoglobulin-
deficient JH2/2 mice29 were nonsuppressive (Fig 5, C, group C).
Furthermore, after the first 100,000g pelleting, we incubated the
exosome-like nanovesicles with monoclonal anti-TNP Ab LC30
in vitro for 30 minutes at 378C and then washed away free Ab
LCbymeans of a second ultracentrifugation step.Very importantly,
these likely Ab LC–sensitized nanovesicles were suppressive
(Fig 5,C, group D, and see Fig E4, group C, in this article’s Online
Repository at www.jacionline.org), whereas comparable antibodyheavy chain–exposed vesicles were not (see Fig E4, groups D
and E).
Lack of inhibition of cell transfer by nanovesicles from the
tolerized JH2/2 donors29 might have been due to a lack of
surface antibody on intrinsically suppressive exosome-like
nanovesicles. Thus we tested the nanovesicles in the non–anti-
gen-specific assay for inhibition of HT-2 T-cell line responsive-
ness to IL-2. Interestingly, despite their inability to suppress CS
effector cell adoptive transfer in vivo, JH2/2 Ts Sup exosome-
like nanovesicles were suppressive in this non–antigen-specific
assay, as were the wild-type TNP Ts Sup nanovesicles (Fig 5,
D, groups B and C vs group A).Antigen affinity chromatography isolates a minor
subpopulation that has all the suppressive activity
We considered that if the exosomes had antigen-specific Ab
LC or antibody on their surface, then they might be antigen
FIG 3. Determination that the Ts Sup suppressive exosome-like nanovesicles are derived from CD81 cells,
are present in plasma of Ts cell donors, and are not produced by Treg cells. A, Treatment of Ts cells from
tolerized mice with anti-CD8 mAb plus complement (C9) before culture to derive Ts Sup eliminated suppres-
sion of adoptively transferred CS (group C). Similar anti-CD4 mAb treatment of the OX-Ts had no effect
(group D). B, Tolerized Ts donor plasma nanovesicles were suppressive (group E), whereas nanovesicles
from other sources (groups C, D, F, and G) were noninhibitory. C, Only TNP–Ts Sup and Ts cell donor
plasma exosome-like nanovesicles inhibited the in vitro HT-2 cell response to IL-2 (groups B and D). D, DE-
REG mice depleted of Treg cells and wild-type mice were tolerized with a high antigen dose and showed
similar suppressive ability (groups C and D).
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the suppressive nanovesicles (Fig 6, A) and recovered an
antigen-binding subfraction (12% of the total) with all the
suppressive activity in the TNP CS model (Fig 6, B, group
D). Furthermore, Fig 6, C, shows that there was suppression
of the HT-2 T-cell response to IL-2 by using the antigen-
binding nanovesicles eluted from the column (Fig 6, C, group
C), whereas the flow through (FT) and column wash fractions
were nonsuppressive (Fig 6, C, groups A and B), confirming
the findings from the CS model.Cloning, sequencing, and bioinformatic comparison
of reads from the exosome-like nanovesicle
populations separated by the TNP antigen affinity
column
Comparison and ranking of the frequency of sequences
between the 2 nanovesicle fractions from the TNP column (ie,
the antigen-binding and antigen-suppressive vs the nonbinding
and nonsuppressive) were performed (see Table E1 in this
article’s Online Repository at www.jacionline.org). This sug-
gested that miRNA-150 (line 7), which was previously associ-
ated with T-cell regulation,31-37 might be a candidate for
mediating suppression by the T cell–derived exosome-like
nanovesicles. In contrast, among the sequences more frequentin the opposite FT versus the eluate sequences was miRNA-
155 (see Table E2, line 12, in this article’s Online Repository
at www.jacionline.org), which therefore was depleted from the
Ts cell nanovesicles. This miRNA is strongly associated with
Treg cells and guides expression of forkhead box protein 3
(Foxp3).38 These data support our findings that Treg cells
were not involved in the CD81 T-cell suppression described
here.Anti-miRs confirm the potential involvement of
miRNA-150 in the suppression by high-dose antigen
tolerization
Fig 7, A, group C, shows that anti-miRs antagonistic to
miR-150 reversed suppression mediated by the exosome-like
nanovesicles in adoptive transfer of CS. In contrast, a set of
5 anti-miR controls aimed at the other prominent miRNAs
more frequent in the column eluate compared with FT vesi-
cles (see Table E1) or mimic controls did not reverse suppres-
sion. Similarly, in addition to these in vivo data, the miR-150
antagonist reversed Ts Sup nanovesicle suppression of the
HT-2 cell response to IL-2, again compared with these
controls (Fig 7, B, group B), suggesting that miR-150 also
was involved in the in vitro inhibition of HT-2 cell responses
to IL-2.
FIG 4. In vivo treatment with suppressive exosome-like nanovesicles inhibits established CS responses in
actively sensitized mice. Ts Sup versus control sham supernatant nanovesicles were injected intraperitone-
ally (i.p.) at 24 hours of an ongoing CS response in actively sensitized and ear-challenged mice. The Ts Sup
exosomes suppressed CS at 48 and 72 hours, whereas the sham supernatant vesicles were noninhibitory.
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definitively identified miR-150 as crucial to in vivo
suppression by the exosome-like nanovesicles
The miR-1502/2 mice31 could not be tolerized (Fig 8, A,
group D) compared with the wild-type control mice (Fig 8, A,
group B), and after attempted tolerization, their exosome-like
nanovesicles were not suppressive compared with those of the
wild-type mice (Fig 8, B, group C vs group B). Very impor-
tantly, these nonsuppressive exosome-like nanovesicles could
be transfected for reconstitution of suppression by mere
in vitro incubation with miR-150 alone (Fig 8, C, group D).
Again, this procedure was performed between the two
100,000g pelleting steps.Performance of the HT-2 assay showed that
miR-150 was also crucial to this in vitro assay
The tolerized miR-1502/2 exosome-like nanovesicles were
nonsuppressive, whereas miR-150 transfection reconstituted
their suppression in vitro (Fig 8, D, group C vs group D).
This finding confirmed that nanovesicle inhibition of the
in vitro correlative HT-2 T-cell assay also was dependent on de-
livery of miR-150. Overall, we have shown that activated
exosome-like nanovesicles from tolerized suppressor T cells
were responsible for the in vivo and in vitro suppression and dif-
fered greatly from normal nanovesicles. The results suggest that
the acquired ability of activated nanovesicles to permit chosen
antibody coating and loading with selected miRNA might be
used to generate very specific therapeutic exosome-like
nanovesicles.DISCUSSION
Synopsis of new findings
This study of T cell–derived immunosuppressive exosome-like
nanovesicles in allergic cutaneous CS generated 2 important
discoveries. First, the nanovesicles were antigen specific, which
enabled them to suppress antigen-specific CS effector T cells and
bind to specific antigen-linked affinity columns. This antigen
specificity resulted from a coating of Ab LC or antibody that we
believe was produced by B cells activated during the tolerogenic
procedure. The second discovery was that these nanovesicles could
easily be transfected with selected miRNAs to therefore deliver a
chosen regulatory double-stranded RNA cargo to genetically affect
particular functions of antigen-specifically targeted cells. Thus
suppressive function depended on the exosome-like nanovesicles
from the Ts cells and B cell–produced antigen-specific Ab LC or
antibody. Use of unprecedented techniques, such as antigen-
specific affinity chromatography of the nanovesicles, led to isola-
tion of a suppressive subset we subjected to molecular cloning.
Deep sequencing and comparative bioinformatics of suppression-
versus non–suppression-associated miRNAs led to preliminary
identification of the inhibitory miRNA as the previously T cell–
associated miRNA-150.31-37Postulated pathway of effector T-cell suppression
by exosome-like nanovesicles
We hypothesize that the described procedure of tolerance
induction results in activation of 2 essential cell types. One is the
CD81 suppressor T-cell population, which produces the
exosome-like nanovesicles containing inhibitory miRNA-150.
FIG 5. The suppressive exosome-like nanovesicles are antigen specific. A, Dual reciprocal antigen specific-
ity of Ts Sup exosome-like nanovesicles. TNP–CS effector cells only, positive control (group A), suppression
in the TNP homologous system (group B), no suppression in the TNP heterologous system (group C), OX–
CS effector cells only, positive control (group D), no suppression in the OX heterologous system (group E),
and suppression in the OX homologous system (group F) are shown. B, Flow cytometric analysis of kappa
light chain expression on TNP–Ts Sup (right, red) and RAW cell–derived (left, blue) nanovesicles. Isotype
controls are shown in gray. MFI, Mean fluorescence intensity. C, Nanovesicles from TNP-tolerized JH2/2
mice did notmediate suppression (group C). In vitro addition of monoclonal anti-TNP Ab LC to nanovesicles
from tolerized JH2/2 mice reconstituted suppression (group D). D, The non–antigen-specific assay of HT-2
T-cell responsiveness to IL-2 showed that nanovesicles from tolerized JH2/2 mice had strong non–antigen-
specific suppressive activity (group C vs group A), which is equivalent to that of wild-type Ts Sup
nanovesicles (group B vs group A).
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antigen-specifically activated in the peritoneal cavity through
contact skin immunization during tolerogenesis.11 After
migration to the spleen, B1 B cells were shown to release
antigen-specific IgM and Ab LC into the circulation.11 Therefore
the suppressive nanovesicles produced during tolerogenesis could
be coated with Ab LC or antibody in vivo, as shown by means of
flow cytometry (Fig 5, B). Moreover, coating of exosome-like
nanovesicles with Ab LC could be performed in vitro (Fig 5, C).
Treatment of the CS effector cell mixture with nanovesicles
was effective in vitro, as shown in adoptive transfer experiments.
Moreover, the exosome-like nanovesicles injected systemically at
the peak response into actively sensitized mice were able to sup-
press CS responses, likely by targeting the activated CS effector T
cells in vivo at the CS elicitation site.
The exact mechanism of tolerance and the targeted cell type are
subject to ongoing research. The CS effector T cells themselves
might be the direct target of the suppressive nanovesicle action.
However, preliminary results suggest that the regulatory signal
could also be transmitted to CS effector cells by targeted antigen-
presenting cells, such as dendritic cells or macrophages, the
functions of which are altered by the suppressive exosome-like
nanovesicles (unpublished data).Antigen specificity of suppressive exosome-like
nanovesicles
The antigen specificity we identified is an important new
property of exosome-like nanovesicles. Not only is this the firstdemonstration of antigen-specific nanovesicles, but also it is the
first demonstration that such vesicles with biological activity can
be separated into at least 2 functional subpopulations: a minor
antigen-binding fraction having all the activity and a major non–
antigen-binding fraction that was nonsuppressive. The potential
surface antigen specificity of the suppressive exosome-like
nanovesicles was based on 4 findings: (1) flow cytometry showing
Ab kappa LC on their surfaces, (2) dual reciprocal antigen-
specific suppressive function, (3) specific antigen binding for
antigen affinity chromatography, and (4) reconstitution of sup-
pression in nonsuppressive nanovesicles from JH2/2
panimmunoglobulin-deficient tolerized mice by coating with
antigen-specific monoclonal Ab LC.
Our data show that nanovesicle antigen specificity and
suppressive activity can be conferred by a coating with free
Ab LC and not antibody heavy chain that therefore likely binds
an unknown site on the activated exosome-like nanovesicles. An
alternative possibility is that intact, antigen-specific IgM or IgG
is responsible. Despite the usual low-affinity antigen binding of
isolated Ab LC, they can mediate antigen specificity.11,39 Fur-
thermore, when Ab LC are multiply displayed on the nanove-
sicle surface, the overall avidity for antigen likely increases,
particularly in this hapten system, where there is only one anti-
gen determinant. Free immunoglobulin light chain previously
has been implicated in a variety of immune and allergic inflam-
matory diseases40-43 and might be one mechanism for the ben-
eficial effect of anti-CD20 B-cell therapy with rituximab.44,45
The effects of Ab LC in diverse responses first were ascribed
to binding and activating mast cells,11,30,40-43,46 but binding of
FIG 6. Isolation of a small suppressive nanovesicle subpopulation by
means of antigen affinity chromatography. A, Suppressive TNP–Ts Sup
nanovesicles were applied to a column conjugated with either TNP or
OX. Only 12% of applied nanovesicles adhered to the TNP column and
were eluted with dilute guanidine. B, TNP–Ts Sup vesicles from the TNP
column FT mediated no suppression (group C), whereas the TNP nanove-
sicles from the eluate had all the activity (group D). The OX column FT,
but not eluate, had all the suppressive activity (group E vs group F).
C, The eluate fraction from the TNP column strongly inhibited HT-2 cell
viability (group C), whereas the column wash (group B) and the FT (group
A) were not suppressive.
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cently demonstrated.47Suppression by antigen-specific exosome-like
nanovesicles
Suppressive nanovesicles can be compared with the immuno-
suppressive extracellular vesicles described previously in allergy
and immunity48-51 and other conditions, such as pregnancy,52-54
breast-feeding,55 and especially cancers, in which tumor-
derived exosomes subvert a variety of host responses.56-62 How-
ever, in none of these other systems have exosomes been shownto exhibit antigen specificity. This was suggested previously but
without antigen binding or dual reciprocal testing.59 Our system
of high-dose antigen-induced suppressive Ts cells and Ts Sup pre-
viously was elegantly characterized biologically and noted to be
antigen specific.63-65 However, neither the mechanisms for anti-
gen specificity (here shown to be antibody) nor elucidation of
how suppression was mediated (here shown because of
miRNA-150 contained in exosome-like nanovesicles) was
determined.Suppression is mediated by miRNA-150 in
exosome-like nanovesicles from tolerized CD81
suppressor T cells
A crucial step leading to the identification of miR-150 as a
mediator of suppression was isolation bymeans of antigen affinity
column chromatography of a suppressive antigen-binding sub-
population of nanovesicles representing only 12% of the total.
Comparing the miRNA sequences of this subpopulation with
those of the nonsuppressive non–antigen-binding nanovesicles
led to miR-150 as a candidate, and inhibition of suppressive
activity by an miR-150 antagonist confirmed this idea. Finally,
experiments with miR-1502/2mice definitively established miR-
150 as the major suppressive small RNA carried by the exosome-
like nanovesicles to antigen-specifically inhibit targeted cells in
the CS effector cell mixture. Of further importance, the
miRNA-150 in the exosome-like nanovesicles also could act
non–antigen-specifically to inhibit HT-2 cell responsiveness to
IL-2, an in vitro assay66 that turned out to be truly correlative
with the in vivo nanovesicle suppression of CS. This should prove
to be an excellent system to determine the molecular mechanisms
of the effects of miR-150 on targeted cells, here possibly taken up
by nonspecific mechanisms, such as pinocytosis, instead of by an
antibody-dependent antigen-specific mechanism. miR-150 was
described originally in positive T-cell mediation of B-cell,
T-cell, and myeloid/erythroid development31,33 and, more re-
cently, development of T, NK, and NKT cells.35,37 As would be
expected for regulation by an miRNA, activating versus suppres-
sive effects might depend on particular targeted transcription fac-
tors other than the strongly miR-150–associated c-Myb.8,31,34,35
Accordingly, miR-150 also can inhibit B-cell development
depending on timing32 and is considered a tumor suppressor.67
The intracellular target of miR-150 in nanovesicle-mediated sup-
pression of CS will be the subject of future investigations.Relation of these studies of T-cell suppression to
human patients with contact dermatitis and other
inflammatory diseases
The present study demonstrates a mechanism of T-cell toler-
ance in mice mediated by exosome-like nanovesicles carrying
miRNA-150 produced by suppressor CD81 T cells and possibly
delivered at the cutaneous site of CS.
Human studies have noted Treg cells defined by Foxp3,
cytokine, or both associations at skin lesions of patients with
contact dermatitis.68 In addition to CD41 Treg cells, there are
many clinical instances in which a role for CD81 Treg cells has
been described. These include regulation of IgE-mediated al-
lergy,69 autoimmunity,70,71 viral diseases,72-74 cancer,75,76 and
transplantation alloimmunity.77 CD81 Treg cells are being appre-
ciated to play a role in a variety of regulatory processes.78-80
FIG 7. Use of specific anti-miRs to test for candidate suppressive cargo of the Ts Sup exosome-like
nanovesicles. A, TNP–Ts Sup nanovesicles preincubated with anti–miR-150 completely inhibited CS sup-
pression (group C). Similar treatment with anti–miR-150* (the antisense passenger strand) only resulted
in 20% reversed suppression (group D). Treatment with anti-miR to miR-92a (group E), Let 7i (group F),
Let 7i* (group G), or the mimic control (group H) did not reverse suppression. B, The same anti-miRs
were tested in the in HT-2 assay. Only the anti-miR to miR-150 reversed suppression (group B).
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ticipation in this tolerogenesis.
Therefore, it is important to consider whether similar antigen-
specific CD81 suppressor T cells or analogous tolerance mecha-
nisms also exist in human subjects and possibly modulate clinical
diseases through the release of comparable exosome-like nanove-
sicles. On the other hand, cell populations mediating regulatory
mechanisms observed in murine models might not always be di-
rectly translatable to human subjects. However, even when differ-
ent regulatory cell types are involved in mediating tolerance, the
same clinical effect can be observed. This was demonstrated in a
clinical trial studying induction of suppression of the autoimmune
response in patients withmultiple sclerosis, in which the same tol-
erogenic procedure was performed in both species but the result-
ing suppressive T cells had distinctly different phenotypes.81,82
Because the activity of the suppressive nanovesicles could also
be modulated by easy transfection with miRNA and surfacecoating with Ab LC, this newly described mechanism of suppres-
sion might have important potential in regulating immune
responses.Translation potentials
The discovery of antigen-specific exosome-like nanovesicles
suggests that they could be targeted to specific cells by sensitizing
their surfaces with a coat of a chosen Ab LC against a marker of
the desired target cells and loaded with selected miRNA cargo for
specific intracellular genetic therapy. This might enable suppres-
sion of specific effector cells in patients with allergic, autoim-
mune, and inflammatory diseases. Alternatively, the suppressive
function of Treg cells in patients with cancer or small RNA
derived from oncogenes in patients with leukemia can be antag-
onized by nanovesicle-derived cargo. Although our findings
pertain to hapten-induced skin allergy, we are extending them
FIG 8. miRNA-1502/2 mice show definitively that miR-150 is the suppressive entity in the exosome-like
nanovesicles from tolerized mice. A, Wild-type C57BL/6 and miR-1502/2 mice were actively contact sensi-
tized and had normal responses at 24 hours (groups A and C). Wild-typemice first tolerized and then actively
sensitized showed strong suppression (group B) in contrast to miR-1502/2 mice, which showed no suppres-
sion after tolerance induction (group D). B, Treatment of OX CS effector cells with miR-1502/2 OX Ts Sup
nanovesicles (group C), as well as withWTNl Cell Sup (group D) andmiR-1502/2Nl Cell Sup (group E) nano-
vesicles did not cause suppression of CS. C, Nanovesicles from OX-tolerized miR-1502/2 mice transfected
with miR-150 mediated suppression, whereas transfection with miR-150* (group E) or miR-mimic control
(group F) did not result in suppression. D, Non–antigen-specific assay of HT-2 T-cell responsiveness to
IL-2 showed that nanovesicles from miR-1502/2 OX-tolerized mice (group C) were noninhibitory, but
transfection with miR-150 rendered them suppressive (group D).
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and allergic asthma (Groot Kormelink et al, unpublished).
The ability of activated exosome-like nanovesicles to be
transfected with selected small RNA cargo to bind surface
antigens preferentially expressed on targeted cells and alter
specific target cell functions could achieve a high therapeutic
index as a new physiologic and specific delivery vehicle.
Finally, our data suggest that therapeutic exosome-like vesicles
are able to act at great distances through the blood for prolonged
times after a single dose and might even work when adminis-
tered orally. Furthermore, as therapy, they seem to be able to
suppress active disease through cooperating immunologic and
genetic mechanisms. In summary, the unique and very impor-
tant potential translational properties of the suppressive
exosome-like nanovesicles that we have described are their
easy transfection with miRNA and, above all, their manipulable
antigen specificity.
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Key messages
d Antigen-specific exosome-like nanovesicles delivering se-
lected inhibitory miRNA represent a new form of regula-
tion shown here to inhibit allergic contact dermatitis.
d The described mechanism of tolerance enables antigen-
specific targeting of particular cell function through
miRNA interference.
d This process might lead to establishment of a new form of
natural immunologic and genetic therapy of many human
diseases.
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Mice
CBA/J, BALB/c, JH2/2,E1 and C57BL/6micewere from theNational Can-
cer Institute, Jackson Laboratories (Bar Harbor, Me), or Jagiellonian Univer-
sity (Krakow, Poland); miR-1502/2 miceE2 were from Klaus Rajewsky
(Jackson Laboratories no. 007750); and DEREG mice depleted of Treg cells
by means of intravenous Diphtheria toxin injection (verified by means of
flow cytometry) were from Tim Sparwasser.E3 Mice were fed autoclaved
food and water. All experiments were performed according to the guidelines
of both Yale and Jagiellonian University.
Reagents
The contact-sensitizing agents TNP-Cl (picryl chloride; Chemica Alta,
Edmonton, Alberta, Canada), trinitrobenzenesulfonic acid, OX, and human
recombinant IL-2 (hrIL-2) were from Sigma (St Louis, Mo), and guanidine
HCl (pH 4.7) was from American Bioanalytical (Natick, Mass).
Media
Mishell-Dutton medium, RPMI 1640, and minimal essential medium with
amino acids were from Sigma. HEPES solution (American Bioanalytical),
FCS, Dulbecco PBS (DPBS), Dulbecco modified Eagle medium, Pen-Strep,
sodium pyruvate, and L-glutamine were all obtained from Gibco Invitrogen
(Auckland, New Zealand).
Antibodies and proteins
The anti-TNP antibody light and heavy immunoglobulin chains were
produced as previously described.E4 Anti-CD9 antibodies were from Santa
Cruz Biotechnology (Santa Cruz, Calif). Hapten-protein conjugates linked
to Sepharose affinity columns (TNP22-BSA and OX18-BSA) were produced
at Jagiellonian University.
Active sensitization and adoptive transfer of CS
responses
After achievement of light ether or metaphane anesthesia, mice were
contact sensitized bymeans of application of 150mL of 5%TNP-Cl or 3%OX
in ethanol/acetone (3:1) to the skin of the shaved abdomen, chest, and feet. On
day 4, theywere ear challengedwith 10mL of 0.4%TNP-Cl or OX in olive oil/
acetone (1:1) on both sides of both ears. The increase in ear thickness after
indicated time points was measured with an engineer’s micrometer (Mitutoyo,
Kawasaki, Japan) and expressed in units of 1022 mm 6 SE.E5-E7
Background nonspecific increase in ear thickness (6 2 units at 24 hours) in
nonsensitized similarly challenged littermates was subtracted from experi-
mental groups to yield a net swelling value.Most ear readingswere done by an
observer completely unaware of the project or protocol (double blinded), and
others were performed by an observer knowledgeable of the protocol but blind
to the groups (single blinded).
For adoptive cell transfers of CS, actively sensitized mice were killed on
day 4 by means of cervical dislocation, and spleens and axillary and inguinal
lymph nodes were harvested for CS effector cells, which were subsequently
transferred intravenously (about 7 3 107 cells per recipient) to naive lightly
anesthetized recipients that were immediately ear challenged with reactive
hapten. Ear thickness was measured as above.E5-E8
Induction of TNP– or OX–Ts cells (TNP-Ts or OX-Ts
cells), TNP–Ts Sup or OX-Ts Sup, and control
normal cell and sham supernatants
For tolerization, isogenic mouse red blood cells were conjugated with TNP
or OXE5 and injected intravenously as 10% suspension on days 0 and 4 into
naive mice, that were skin painted with homologous hapten on day 9. Spleens
and lymph nodes containing induced Ts cells were harvested on day 11, and
single-cell suspensions were prepared for culture at 2 3 107 per milliliter in
serum free Mishell-Dutton medium supplemented with pyruvic acid, gluta-
mine, minimal essential medium with additional amino acids,
2-mercaptoethanol, HEPES, and Pen-Strep for 48 hours at 378C in 5% CO2to produce Ts Sup. Subsequently, Ts Sup was separated from cells and debris
by means of centrifugation and stored at 48C if used within 2 to 4 days, at
2208C if used within 10 days, or at 2708C for longer times.E1,E2,E9-E11
In TNP– and OX–Ts Sup no uniformly increased levels of IL-10, TGF-b, or
IL-6 were found by means of sensitive ELISA (BD PharMingen, San Jose,
Calif). The sensitivities of the ELISAs usedwere 15 pg/mL (IL-10 and IL-6) and
30 pg/mL (TGF-b). For a control, normal cells from naive mice were cultured
identically to generateNlCell Sup and eventually processed to nanovesicles. For
an additional control, sham-tolerized mice received intravenous injections of
isogenic mouse red blood cells treated chemically as for hapten conjugation but
without hapten, and subsequently, skin painted with vehicle alone. Nl Cell Sup
and sham supernatant nanovesicles were isolated as described above.
Separation of vesicles from cell supernatant or
fresh plasma
Supernatants from 48-hour cell cultures in serum-free Mishell-Dutton
medium or plasma diluted 1:1 in DPBS were centrifuged at 300g and then at
10,000g for 30minutes, followed by sequential filtration of the cell-free super-
natant or plasma with 0.45- and 0.22-mm filters. Nanovesicles were then sep-
arated by means of double ultracentrifugation in a Beckman L870M
ultracentrifuge at 100,000g at 48C for 70 minutes.E12 The final pellet of en-
riched nanovesicles was resuspended in DPBS.
Quantitative description of immune cell treatment
with nanovesicles in adoptive experiments
Culture of spleen and lymph node cells (23 107 per milliliter) from 40 to-
lerized mice yielded approximately 400 mL of supernatant that was applied to
the nanovesicle enrichment procedure. This resulted in 4000 mL of resus-
pended final 100,000g pellets containing approximately 1.75 3 1012 vesicles
(estimated by using NTAE13). In a typical adoptive transfer we used 30 mL of
resuspended pellet (about 1.33 1010 nanovesicles) per 73 107 effector cells
per recipient. After incubation for 30 minutes at 378C, excess nanovesicles
were removed from the immune cells by means of centrifugation at 300g,
and the remaining vesicle-exposed CS effector cells were transferred intrave-
nously to naive recipients to determine the effect of the nanovesicles on the
adoptive cell transfer of CS responses.
Invitronon–antigen-specificbioassaytoestimate the
suppressive activity of exosome-like nanovesicles
This in vitro assay developed by usE14 and confirmed by othersE15measured
the strength of non–antigen-specific suppression of the HT-2 T-cell line
(American Type Culture Collection, Manassas, Va) responsiveness to IL-2
by exosome-like nanovesicles from tolerizedmice. HT-2 T cells were cultured
in high-glucose Dulbecco modified Eagle medium with 5% FCS (centrifuged
at 100,000g to remove vesicles) and 100 U/mL hrIL-2. At least 2 hours before
the test IL-2 was removed from cell culture by proper washing with IL-2 free
medium. Then 104 cells (50mL) were plated per microwell into 100mL of me-
dium containing 3 U/mL hrIL-2, and then nanovesicles were added to the first
well in a volume of 50mL. The starting vesicle concentrationwas estimated by
using NTA before serial 3-fold dilutions. Plates were incubated at 378C in 5%
CO2, and after 18 hours, 20 mL of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was added to each well. After another 3
to 3.5 hours, 120mLof acidic isopropanolwith 0.04mol/LHClwas added, and
the mixture was incubated overnight in darkness at 258C. The absorbance of
developed dark blue dye was measured at 570 nm, and results were compared
with the standard curve. The end point of the assay was the last titered well
containing the lowest number of exosomes that led to 50% viability of HT-2
cells. In the standard curve supplementation of HT-2 cells alone with 3 U/
mL hrIL-2 represented 100% viability, whereas no hrIL-2 resulted in 0% via-
bility. Then, after processing as above, themiddle value of absorbance between
0% and 100%was taken as the 50% viability point to be used as the assay end
point. This was repeated at each testing of nanovesicles. The strength of sup-
pression was inversely proportional to the number of nanovesicles needed to
reach the end point of 50% viability, which was expressed as the suppressive
end point (ie, the number of exosomes 3 106 per 104 HT-2 cells).
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TNP–Ts Sup exosome-like nanovesicles on TNP-
Sepharose and OX-Sepharose affinity columns
TNP-conjugated BSA (TNP22-BSA) and OX-conjugated BSA (OX18-
BSA) were linked to cyanogen bromide–activated Sepharose 4FF (fast flow;
Pharmacia, Uppsala, Sweden), according to the manufacturer’s procedure.
TNP–Ts Sup exosome-like nanovesicles were separated on different affinity
syringe columns to avoid cross-contamination. Each run used 15 mL of
TNP–Ts Sup filtered through a 0.22-mm filter, omitting the 100,000g centrif-
ugation step to avoid vesicle aggregation. The column FTwas that portion of
the applied nanovesicles that passed through the columns. Then the columns
were washed with 6 3 5 mL of DPBS and eluted with guanidine (pH 4.7) at
48C, which resulted in 2 fractions per column: the FT and the eluate.
Molecular cloning of the antigen affinity column
eluate versus FT fractions
RNAobtained from the suppressive exosome-like nanovesicle eluate versus
the nonsuppressive FT fractions from the TNP antigen affinity column was
sequenced.E16 RNAs at less than 100 bp from a polyacrylamide sizing gel were
isolated to include pre-miRNA and mature miRNA species for cDNA in this
size range. First, they were ligated to synthetic oligonucleotide at the 59 ends
and then ligated to another synthetic oligonucleotide at the 39 ends. Primers
complementary to the oligonucleotides were used for reverse transcriptase re-
actions, and then PCR was used to augment cDNA sequencing by means of
Solexa (Illumina, San Diego, Calif). The cDNAs were ligated in a plasmid
under the control of a T7 promoter. Then they were amplified and converted
to RNA for bioassays attempting to determine the RNA sequence or sequences
that in number pertain to the Ts Sup suppressive exosome-like nanovesicles in
the eluate greater than those from the FT or vice versa.
Bioinformatic analysis of eluate versus FT
sequences from TNP-antigen affinity column
separation of suppressive TNP–Ts Sup nanovesicles
Solexa deep sequencing of the TNP affinity column–separated exosome-
like nanovesicle miRNA of the eluate versus FT column produced 3,394,296
total reads (409,476 eluate and 2,984,820 FT), with 379,153 unique reads.E17
Sequence lengths ranged between 16 and 25 nucleotides, with a median length
of 20 nucleotides. Bowtie (version 0.12.5 of miRBase, http://microrna.sanger.
ac.uk/sequences/) was used to map individual reads onto the mouse reference
genome (mm9) fromUCSC (mouse genome, http://hgdownload.cse.ucsc.edu/
downloads.html#mouse) and mouse miRNA sequences in miRBase (release
15 of miRBase, http://microrna.sanger.ac.uk/sequences/). All unique align-
ments without mismatch were retained for further analysis. Bowtie mapped
22% of the unique reads onto the mouse genome and 0.6% onto 222 distinct
mouse miRNAs.E18 The miRNA reads were kept for further analysis if they
met 2 criteria: (1) they could be mapped onto any of the mouse miRNAs with-
out considering the reverse complement, and (2) they did not map onto other
positions in the mouse reference genome. These miRNA sequences accounted
for 25,963 total reads (1,148 unique reads) and covered 187 distinct mouse
miRNAs. Differential expression analysis was carried out with edgeR (version
1.6.5)E18 to compare TNP-eluate and FT samples. Significance required a P
value of less than .01 and a false discovery rate of less than 0.05. Because these
data did not include replicates, a common dispersion of 0.1 was assumed, as
recommended in the edgeR user’s guide for genetically identical model orga-
nisms. This was consistent with the value of 0.14 estimated for the 50miRNAs
with the lowest absolute fold differences in the eluate versus FT. miRNAs pre-
viously associated with exosomes were identified by using ExoCarta.E19
Attempted blockage of CS suppression by TNP–Ts
Sup exosome-like nanovesicles by using in vitro
incubation with anti–miR-150
Various anti-miRs (Dharmacon/Thermo Fisher, Uppsala, Sweden) were
used to attempt blocking of the biological activity of specific miRNAs present
in the mixed suppressor TNP–Ts Sup nanovesicle pool. Per each recipient, weincubated 3 mg (equals 0.2 nmol/L) of specific anti-miRs or control with
exosome-like nanovesicles from the 0.22-mmfilter.We used the 100,000g pel-
let from TNP–Ts Sup in a 378C water bath for 1 hour, followed by a second
ultracentrifugation in DPBS at 100,000g at 48C for 70 minutes to remove
the free anti-miRs. The resuspended pellets of anti-miR–treated nanovesicles
were then incubated with 7 3 107 TNP CS effector cells for 30 minutes in a
378C water bath. Then the CS effector cells were washed at 300g with
DPBS to remove the non–cell-associated anti-miR–treated nanovesicles and
used for intravenous adoptive transfer to naive recipients.
Transfection of miR-1502/2 OX–Ts Sup exosome-
like nanovesicles with synthetic miRNA-150
OX–Ts Sup nanovesicles from OX-tolerized miR-1502/2mice were trans-
fected with synthetic miR-150, miR-150*, or miR mimic negative control.
Nanovesicles derived from 15 mL of supernatants for each group of 5 mice
had been processed to the first 100,000g ultracentrifugation pellets, which, af-
ter resuspension with 150 mL of DPBS, were incubated with 3 mg (equals 0.2
nmol/L) per recipient of miRNA (22 bp, Dharmacon/Thermo Fisher) in a 378C
water bath for 1 hour. This was followed by a second ultracentrifugation in
DPBS at 100,000g at 48C for 70 minutes to remove the free miRNA. Then
the transfected exosome-like nanovesicles from the second pellet were used
for incubationwith OXCS effector cells at 378C for 30minutes. After washing
by means of centrifugation at 300g with DPBS, the cells exposed to trans-
fected nanovesicles were adoptively transferred into naive recipients.
Statistical analysis
Each mouse provided a statistical ‘‘n’’ of 1. Thus after ear challenge, the
thickness of each ear of each mouse was measured in duplicate by a blinded
observer using a micrometer (Mitutoyo). Four measurements per mouse were
pooled to determine the mean ear swelling for each mouse, which was a
reflection of CS inflammation. The average ear swelling expressed as the D6
SE (after subtraction of the negative control value) was calculated for each
group. We used 4 to 6 mice for each experimental and control group. All
experiments were carried out 2 to 4 times. The 2-tailed Student t test, ANOVA,
and post hoc RIR Tukey tests were used to assess the significance of differ-
ences between groups, with P values of less than .05 taken as the minimum
level of statistical significance.
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FIG E1. TNP–Ts Sup exosomes mediate a dose-dependent inhibition of TNP CS effector cells. High-dose Nl
Cell nanovesicles did not mediate suppression (group C), whereas TNP–Ts nanovesicles administered at a
dose 72 3 107 per recipient (group D) and serially 5-fold diluted (groups E and F) showed dose-dependent
suppression.
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FIG E2. An antigen-specific in vitro assay confirms that the 100,000g pellet exosome-like nanovesicles have
all the suppressive activity of the Ts Sup. TNP-conjugated dendritic cells (DC) and TNP CS effector cells were
cocultured in the presence or absence of TNP-Ts nanovesicles or control Nl Cell Sup nanovesicles. IFN-g
was measured as a read out for CS-effector cell activation. The 4 experiments shown confirmed in vitro
the suppressive antigen-dependent activity of exosome-like nanovesicles derived from the Ts Sup.
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FIG E3. In vivo treatment with suppressive exosome-like nanovesicles shows prolonged inhibition of estab-
lished CS responses in actively sensitized mice. A, TNP–Ts Sup versus control sham supernatant nanove-
sicles were injected intraperitoneally in a single dose at 24 hours of an ongoing CS response of actively
sensitized and ear-challenged mice. Only TNP–Ts Sup nanovesicles significantly suppressed CS up to
120 hours. B, TNP–Ts Sup nanovesicles were injected intraperitoneally or intravenously or administered
orally with a single dose at 24-hour responses of an ongoing CS response in actively sensitized and ear-
challenged mice. Treatment through all routes was successful, with the intraperitoneal route being most ef-
fective. i.p., Intraperitoneal; i.v., intravenous.
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FIG E4. Anti-TNP mAb light chains (LC), but not heavy chains (HC), sensitize exosome-like nanovesicles for
suppression of adoptive CS. Nanovesicles harvested from tolerized JH2/2mice were pelleted and sensitized
in vitrowith various doses of anti-TNP antibody light or heavy chains before washing of the unbound chains
at 100,000g. Only sensitizing the nanovesicles with antibody light chains restored their suppressive capacity
(group C).
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TABLE E1. Mouse miRNAs significantly upregulated in the TNP antigen affinity column eluate compared with the FT
Log (concentration) Log (fold change) P value FDR No. of reads, FTX No. of reads, ETX
mmu-mir-92a-1 212.70 5.79 1.76E-12 3.19E-10 60 457
mmu-mir-33 216.44 8.13 3.41E-12 3.19E-10 2 77
mmu-mir-27a 215.36 5.96 1.89E-10 1.18E-08 9 77
mmu-mir-484 216.19 6.00 7.51E-10 3.51E-08 5 44
mmu-mir-296 231.74 36.54 5.26E-09 1.40E-07 0 36
mmu-mir-92a-2 217.20 6.62 7.60E-08 1.78E-06 2 27
mmu-mir-150 213.11 3.69 8.95E-07 1.67E-05 94 167
mmu-mir-210 217.95 7.11 1.72E-06 2.52E-05 1 19
mmu-mir-486 217.95 7.11 1.72E-06 2.52E-05 1 19
mmu-let-7b 213.83 3.54 2.94E-06 3.67E-05 60 96
mmu-mir-184 232.29 35.46 5.19E-06 6.06E-05 0 17
mmu-let-7i 211.32 3.17 9.88E-06 1.09E-04 389 479
mmu-mir-423 214.17 3.39 1.15E-05 1.19E-04 50 72
mmu-mir-500 232.48 35.07 4.53E-05 4.46E-04 0 13
mmu-mir-153 232.60 34.83 1.65E-04 1.47E-03 0 11
mmu-mir-328 217.78 4.28 1.01E-03 8.55E-03 3 8
mmu-mir-222 216.38 3.09 1.18E-03 9.56E-03 12 14
mmu-mir-1964 232.83 34.37 1.41E-03 1.10E-02 0 8
mmu-mir-221 215.31 2.50 2.35E-03 1.69E-02 31 24
mmu-mir-339 217.42 3.54 4.07E-03 2.53E-02 5 8
mmu-mir-147 233.04 33.96 6.15E-03 3.38E-02 0 6
mmu-mir-98 218.12 3.60 9.22E-03 4.93E-02 3 5
The P values were adjusted for multiple testing by using the Benjamini and Hochberg approach for controlling the false discovery rate and are exact P values computed by using
edgeR.
ETX, Eluate column; FDR, false discovery rate; FTX, FT column; Log (concentration), overall concentration for an miRNA across the 2 groups being compared; Log (fold change),
log fold change for the counts between groups.
J ALLERGY CLIN IMMUNOL
VOLUME 132, NUMBER 1
BRYNIARSKI ET AL 181.e8
TABLE E2. Mouse miRNAs significantly upregulated in the TNP antigen affinity column FT (FTX) compared with the eluate (ETX)
Log (concentration) Log (fold change) P value FDR No. of reads, FTX No. of reads, ETX
mmu-mir-29a 210.63 24.74 9.81E-10 3.67E-08 9766 50
mmu-mir-148a 213.75 25.14 5.23E-09 1.40E-07 1288 5
mmu-mir-26b 212.99 23.90 8.93E-07 1.67E-05 1411 13
mmu-mir-148b 215.89 25.51 1.76E-06 2.52E-05 333 1
mmu-mir-340 216.00 25.29 2.88E-06 3.67E-05 285 1
mmu-mir-696 232.48 235.08 1.60E-04 1.47E-03 95 0
mmu-mir-2133-2 214.35 22.59 1.90E-03 1.42E-02 350 8
mmu-mir-20a 215.55 23.01 2.47E-03 1.71E-02 176 3
mmu-mir-29c 216.74 23.81 3.49E-03 2.33E-02 102 1
mmu-mir-191 215.03 22.58 3.82E-03 2.46E-02 218 5
mmu-mir-712 214.49 22.30 5.10E-03 3.07E-02 287 8
mmu-mir-155 233.10 233.83 5.48E-03 3.10E-02 40 0
mmu-mir-362 233.10 233.83 5.48E-03 3.10E-02 40 0
Shown here are miRNA sequences more frequent in the FT versus the eluate. For column descriptions, please see the footnote for Table E1.
ETX, Eluate column; FDR, false discovery rate; FTX, FT column.
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